Blended Huemanity's masks use zinc woven into the material to kill microbes of the virus. Photo via blendedhuemanity.com

Two Houston companies have joined forces to create a new line of protective face masks that are able to deactivate the coronavirus.

Accel Lifestyle and Ascend Performance Materials have partnered to create Blended Huemanity, which has released its Acteev Protect™ Nonwoven Mask.

"The partnership between Accel Lifestyle and Ascend Performance Materials brings together two powerhouse companies, with expertise in science, fabric, manufacturing, branding and consumer products," says Megan Eddings, founder and CEO of Accel Lifestyle, in a statement. "If the last few months have shown us anything, the need for face coverings isn't going anywhere. We all want to return to normal life — sporting events, family gatherings, hugs with friends — but we want to do so safely and comfortably."

The mask's design incorporates natural ingredients in the Acteev™ technology that the University of Cambridge has confirmed can eliminate COVID-19, SARS-CoV-2, with 99.9 percent efficacy. Ascend is currently seeking the appropriate regulatory protocols with the U.S. Environmental Protection Agency, the U.S. Food and Drug Administration and other governmental agencies.

"Acteev's active layer of defense uses safe, environmentally friendly active zinc ions embedded into the matrix of the polymer – not a chemical spray that will wash away or flake off — meaning these masks can be used again and again," says Phil McDivitt, CEO of Ascend, the company that invented Acteev™ technology, in the release.

Comfort and efficiency were both priorities for the design.

"Even the best masks only offer protection if they're worn, and the Acteev Protect™ Nonwoven Mask is so soft and breathable that it's comfortable to wear for hours," McDivitt says in the release. "They are a great choice for teachers, restaurant staff, transportation workers and anyone whose lifestyle takes them out of their homes and into the world."

The company is currently selling the masks for $99 for a pack of 25. They are available online for health care workers or citizens alike.

"We are wildly excited about protecting not only our frontline healthcare workers but the entire population," says Eddings in the release. "Both Phil McDivitt and I, along with our teams, have a passion for creating products that serve the health and protection of humanity. The fact that we are able to combine our team's resources and strengths and produce products that will truly save lives is profound and beautiful."

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”